impact of checkmate-238 results for patients with melanoma
Published 7 years ago • 96 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
1:19
how the results of combi-ad and checkmate-238 will impact melanoma care
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
0:56
dr. weber on checkmate-238 for melanoma
-
1:17
dr. weber on checkmate-238 compared to other trials in melanoma
-
7:04
checkmate 238: adjuvant checkpoint therapy after melanoma resection
-
1:42
dr. weber on biomarker data from checkmate-238 for melanoma
-
1:05
dr. weber on rationale for the checkmate-238 trial in melanoma
-
2:03
7-y results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
3:02
checkmate 238 results presented at esmo 2017
-
5:30
jeffrey s weber, asco 2018 – resected stage iii melanoma and the checkmate 238 trial
-
1:59
checkmate 238: nivolumab versus ipilimumab in stage iii melanoma
-
3:40
aacr 2023 highlights on advances in the treatment of resected high-risk melanoma with jeffrey weber
-
2:18
dr. jeffrey weber on checkmate-064 trial for advanced melanoma
-
1:16
nivolumab in the adjuvant setting for melanoma
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
2:12
phase iii combi-d study of dabrafenib and trametinib in patients with melanoma
-
2:01
checkmate 172 trial of nivolumab for advanced melanoma: preliminary results
-
4:14
adjuvant therapy for melanoma: novel treatment options
-
2:10
ipilimumab combined with nivolumab for patients with melanoma